Axel Grothey

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Do all patients with metastatic colorectal cancer need chemotherapy until disease progression?
    Tara Beers Gibson
    CIG Media Group, LP Dallas, TX, USA
    Clin Colorectal Cancer 6:196-201. 2006
  2. ncbi request reprint A review of oxaliplatin and its clinical use in colorectal cancer
    Axel Grothey
    Mayo Clinic, Rochester, MN, USA
    Expert Opin Pharmacother 5:2159-70. 2004
  3. doi request reprint A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer
    Axel Grothey
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Nat Clin Pract Oncol 6:10-1. 2009
  4. pmc Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care
    Axel Grothey
    Mayo Clinic, Rochester, Minnesota, USA Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA University Hospital Gasthuisberg Leuven, Leuven, Belgium Léon Bérard Centre and Claude Bernard University, Lyon, France IRCCS San Martino, Genoa, Italy
    Oncologist 19:669-80. 2014
  5. doi request reprint Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Nat Rev Clin Oncol 6:507-18. 2009
  6. doi request reprint Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107
    Axel Grothey
    Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 26:183-9. 2008
  7. ncbi request reprint Clinical management of oxaliplatin-associated neurotoxicity
    Axel Grothey
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Clin Colorectal Cancer 5:S38-46. 2005
  8. ncbi request reprint Biological therapy and other novel therapies in early-stage disease: are they appropriate?
    Axel Grothey
    Department of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Clin Cancer Res 13:6909s-12s. 2007
  9. ncbi request reprint Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 21:553-64, 566; discussion 566-8, 577-8. 2007
  10. ncbi request reprint Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 20:21-8. 2006

Detail Information

Publications99

  1. ncbi request reprint Do all patients with metastatic colorectal cancer need chemotherapy until disease progression?
    Tara Beers Gibson
    CIG Media Group, LP Dallas, TX, USA
    Clin Colorectal Cancer 6:196-201. 2006
    ..Both studies demonstrated that chemotherapy can be administered intermittently without affecting the overall efficacy of treatment...
  2. ncbi request reprint A review of oxaliplatin and its clinical use in colorectal cancer
    Axel Grothey
    Mayo Clinic, Rochester, MN, USA
    Expert Opin Pharmacother 5:2159-70. 2004
    ....
  3. doi request reprint A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer
    Axel Grothey
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Nat Clin Pract Oncol 6:10-1. 2009
    ..Oncologists will probably have to use a lower starting dose of capecitabine in combination therapies that include oxaliplatin, than that used in this study...
  4. pmc Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care
    Axel Grothey
    Mayo Clinic, Rochester, Minnesota, USA Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA University Hospital Gasthuisberg Leuven, Leuven, Belgium Léon Bérard Centre and Claude Bernard University, Lyon, France IRCCS San Martino, Genoa, Italy
    Oncologist 19:669-80. 2014
    ....
  5. doi request reprint Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Nat Rev Clin Oncol 6:507-18. 2009
    ..Nonetheless, anti-VEGF therapy has enhanced the arsenal of anticancer therapies and has provided new insights into the biology of malignancy...
  6. doi request reprint Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107
    Axel Grothey
    Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 26:183-9. 2008
    ..As these two superior therapies have differing mechanisms of action, we explored whether the improved survival associated with the superior therapy was dependent on tumor response...
  7. ncbi request reprint Clinical management of oxaliplatin-associated neurotoxicity
    Axel Grothey
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Clin Colorectal Cancer 5:S38-46. 2005
    ....
  8. ncbi request reprint Biological therapy and other novel therapies in early-stage disease: are they appropriate?
    Axel Grothey
    Department of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Clin Cancer Res 13:6909s-12s. 2007
    ....
  9. ncbi request reprint Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 21:553-64, 566; discussion 566-8, 577-8. 2007
    ..Definitive conclusions on the sequence and duration of front-line therapy and the most effective strategy to ameliorate toxicity await results of ongoing prospective clinical trials...
  10. ncbi request reprint Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 20:21-8. 2006
    ....
  11. ncbi request reprint Is there a third-line therapy for metastatic colorectal cancer?
    Axel Grothey
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Semin Oncol 33:S36-8. 2006
    ..Data from randomized trials on third-line treatment are needed...
  12. ncbi request reprint Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Semin Oncol 33:S41-9. 2006
    ..Mechanistic studies in humans will be aided by the development and validation of surrogate clinical end points such as noninvasive assessment of hemodynamics and vascular changes within tumors, using imaging studies...
  13. doi request reprint Does stage II colorectal cancer need to be redefined?
    Axel Grothey
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 17:3053-5. 2011
    ..If validated, these results could have significant implications for the selection of patients for adjuvant therapy in this disease...
  14. doi request reprint Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Stat Methods Med Res 17:529-35. 2008
    ..Thus, the practicing oncologist needs to be aware of the limitations in the definition of surrogate endpoints in the adjuvant setting...
  15. ncbi request reprint Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 22:1209-14. 2004
    ..However, the importance of the availability of all three active cytotoxic agents, FU-LV, irinotecan, and oxaliplatin, on overall survival (OS) has not yet been evaluated...
  16. doi request reprint Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 26:5326-34. 2008
    ..1 months was reported. The association between various pre- and post-treatment factors (including the use of bevacizumab beyond first progression [BBP]) and survival was examined...
  17. ncbi request reprint Oxaliplatin plus oral fluoropyrimidines in colorectal cancer
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Colorectal Cancer 4:S37-42. 2004
    ..This review will detail the results of these trials focused on capecitabine-based combinations...
  18. doi request reprint Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies
    Axel Grothey
    Department of Oncology, Mayo Clinic Rochester, Rochester, Minnesota, USA
    Cancer J 14:170-7. 2008
    ....
  19. doi request reprint Reintroduction of oxaliplatin: a viable approach to the long-term management of metastatic colorectal cancer
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Oncology 79:389-99. 2010
    ..This paper presents a critical review of the evidence to support the utility of treatment interruption and reintroduction of oxaliplatin for the long-term management of mCRC...
  20. pmc Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database
    Qian Shi
    Qian Shi, Axel Grothey, Brian M Bot, and Daniel J Sargent, North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN Thierry Andre, Hopital Saint Antoine, Paris, France Greg Yothers and Michael J O Connell, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh Daniel G Haller, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA Stanley R Hamilton, University of Texas MD Anderson Cancer Center, Houston, TX Brian M Bot, Sage Bionetworks Jacqueline K Benedetti, Southwest Oncology Group Statistical Center, Seattle, WA Eric Van Cutsem, University Hospital Gasthuisberg, Gasthuisberg, Belgium and Chris Twelves, St James s University Hospital, Leeds, United Kingdom
    J Clin Oncol 31:3656-63. 2013
    ....
  21. ncbi request reprint End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group
    Daniel J Sargent
    Department of Health Sciences Research, North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 25:4569-74. 2007
    ..We previously validated disease-free survival (DFS) after 3-year follow-up as an excellent predictor of 5-year OS results. Here we explore shorter term DFS and OS end points, as well as stage dependency...
  22. ncbi request reprint Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer
    Amanda C Ashley
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 110:670-7. 2007
    ..Efficacy and toxicity of oxaliplatin (Eloxatin; Sanofi-Aventis, Paris, France) combined with irinotecan (IROX) were examined in 383 patients enrolled on the IROX arm of Intergroup Study N9741...
  23. pmc Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials
    Daniel Sargent
    Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    J Clin Oncol 27:872-7. 2009
    ..Limited data are available on the time course of treatment failures (recurrence and/or death), the nature and duration of adjuvant treatment benefit, and long-term recurrence rates in patients with resected stage II and III colon cancer...
  24. pmc Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance)
    Charles L Loprinzi
    Charles L Loprinzi, Rui Qin, Pamela Atherton, Drew Seisler, and Axel Grothey, Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN Shaker R Dakhil, Wichita Community Clinical Oncology Program, Wichita, KS Louis Fehrenbacher, Kaiser Permanente Vallejo, Vallejo, CA Kathleen A Flynn, Michigan Cancer Research Consortium, Ann Arbor, MI Rubina Qamar, Aurora Cancer Care Milwaukee West, Wauwatosa, WI and Grant C Lewis, Summit Cancer Care, Savannah, GA
    J Clin Oncol 32:997-1005. 2014
    ..Intravenous calcium and magnesium have been extensively used to reduce oxaliplatin-induced neurotoxicity. This trial was designed to definitively test whether calcium/magnesium decreases oxaliplatin-related neurotoxicity...
  25. pmc Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial
    Steven R Alberts
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    JAMA 307:1383-93. 2012
    ..Leucovorin, fluorouracil, and oxaliplatin (FOLFOX) is the standard adjuvant therapy for resected stage III colon cancer. Adding cetuximab to FOLFOX benefits patients with metastatic wild-type KRAS but not mutated KRAS colon cancer...
  26. pmc Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741
    James M Heun
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Oncologist 16:859-67. 2011
    ....
  27. doi request reprint Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Lancet 381:303-12. 2013
    ..An international phase 3 trial was done to assess the multikinase inhibitor regorafenib in these patients...
  28. pmc Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer
    Daniel J Sargent
    Division of Biomedical Statistics and Informatics, Department of Pathology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:3219-26. 2010
    ..We examined MMR status as a predictor of adjuvant therapy benefit in patients with stages II and III colon cancer...
  29. pmc Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators
    Aditya Bardia
    Department of Oncology, Johns Hopkins University, Baltimore, MD, USA
    Semin Oncol 37:39-46. 2010
    ..Validation studies are needed to clarify the discrepancy and to assess the accuracy of these tools for predicting actual patient outcomes...
  30. ncbi request reprint Developments in combination chemotherapy for colorectal cancer
    Matthew P Goetz
    Mayo Clinic College of Medicine, Department of Oncology, 200 First Street Southwest, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 4:627-37. 2004
    ..Further adjuvant studies are testing the benefit of the addition of biologic therapies to oxaliplatin and irinotecan-based combination chemotherapy...
  31. ncbi request reprint FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer
    Axel Grothey
    Mayo Clinic College of Medicine, Department of Medical Oncology, Rochester, MN, USA
    J Clin Oncol 23:3311-3. 2005
  32. pmc Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse
    Sumithra J Mandrekar
    Sumithra J Mandrekar, Jeffrey Meyers, Axel Grothey, and Daniel J Sargent, Mayo Clinic, Rochester, MN Ming Wen An, Vassar College, Poughkeepsie, NY and Jan Bogaerts, European Organisation for Research and Treatment of Cancer, Brussels, Belgium
    J Clin Oncol 32:841-50. 2014
    ..The data warehouse assembled to guide the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was used...
  33. ncbi request reprint Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505)
    Deirdre R Pachman
    Department of Oncology, Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA
    Support Care Cancer 24:5059-5068. 2016
    ..Oxaliplatin and paclitaxel are commonly used chemotherapies associated with acute and chronic neuropathies. There is a need to better understand the similarities and differences of these clinical syndromes...
  34. pmc ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer
    Lindsay A Renfro
    Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN LAR, DJS Department of Oncology, Mayo Clinic, Rochester, MN AMG, SRA, CLL Department of Statistics, University of Virginia, Charlottesville, VA YX Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY LBS Hôpital Saint Antoine, Paris, France Pierre and Marie Curie University, Paris, France TA Leeds Institute of Cancer and Pathology, University of Leeds and St James s University Hospital, Leeds Cancer Research UK Centre, UK CT Oncology Unit, Ospedale Giovanni XXIII, Bergamo, Italy RL Division of Hematology and Oncology, University of Florida, Gainesville, FL CJA National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Pittsburgh, PA GY
    J Natl Cancer Inst 106:. 2014
    ....
  35. pmc Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7
    Axel Grothey
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    J Clin Oncol 29:421-7. 2011
    ..In a nonrandomized, retrospective study, intravenous (IV) calcium/magnesium (Ca/Mg) was associated with reduced oxaliplatin-induced sNT...
  36. ncbi request reprint N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer
    Steven R Alberts
    Department of Medical Oncology, North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
    Clin Colorectal Cancer 5:211-3. 2005
  37. pmc Comparison of error rates in single-arm versus randomized phase II cancer clinical trials
    Hui Tang
    Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    J Clin Oncol 28:1936-41. 2010
    ..Given a large enough patient pool, the randomized phase II designs provide a more accurate decision for screening agents before phase III testing...
  38. ncbi request reprint First- and second-line therapy of metastatic colorectal cancer
    Shelby Terstriep
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Expert Rev Anticancer Ther 6:921-30. 2006
    ..These advances have increased the overall survival of advanced colorectal cancer patients, which was once 6 months with best supportive care, to over 2 years if all active agents are used in the course of the disease...
  39. ncbi request reprint A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147
    Robert R McWilliams
    Mayo Clinic, Rochester, MN Division of Medical Oncology, Mayo Clinic, Rochester, MN
    J Clin Oncol 30:446. 2012
    ..N0147 is a phase III adjuvant trial for stage III CRC patients (N=3397) in which patients completed questionnaires and tumor variables and KRAS/BRAF mutation status was assessed...
  40. pmc Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)
    Adam M Lee
    aDepartment of Molecular Pharmacology and Experimental Therapeutics MPET, Mayo Clinic Cancer Center bAlliance Statistics and Data Center cDivision of Medical Oncology dDivision of Gastroenterology, Mayo Clinic, Rochester, Minnesota eDepartment of Surgery, Cancer Prevention and Control Program, University of Hawaii Cancer Center, Honolulu, Hawaii fDepartment of Medicine, Center for GI Oncology, The University of Chicago Medicine, Chicago, Illinois gDivision of Hematology Oncology, Vanderbilt Ingram Cancer Center, Nashville, Tennessee hSurgical Oncology Associates of South Texas, San Antonio, Texas iDepartment of Hematology Oncology, Lehigh Valley Health Network, John and Dorthy Morgan Cancer Center, Allentown, Pennsylvania jDepartment of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan kDepartment of Hematology Oncology, Division of Medical Oncology, The Ohio State University Medical Center, Columbus, Ohio, USA lDepartment of Medicine, Division of Medical Oncology, University of British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Pharmacogenet Genomics 26:133-7. 2016
    ..1129-5923 C>G/hapB3 and overall grade≥3 AE rate. Our results suggest that c.1129-5923 C>G/hapB3 have limited predictive value for severe toxicity to 5-FU-based combination chemotherapy. ..
  41. pmc A home-based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial
    Andrea L Cheville
    Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota, USA
    J Pain Symptom Manage 45:811-21. 2013
    ..Exercise benefits patients with cancer, but studies of home-based approaches, particularly among those with Stage IV disease, remain small and exploratory...
  42. doi request reprint Curable metastatic colorectal cancer
    Matthew J Eadens
    Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 13:168-76. 2011
    ..Prospective randomized trials are needed to further clarify the roles of these novel treatment options in the clinician's repertoire for metastatic CRC...
  43. doi request reprint North Central Cancer Treatment Group--achievements and perspectives
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 35:530-44. 2008
    ....
  44. doi request reprint Antiangiogenesis agents in colorectal cancer
    Joleen Hubbard
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Oncol 22:374-80. 2010
    ..Additionally, there are numerous other angiogenesis agents targeting VEGF and other proangiogenic systems in clinical development...
  45. pmc Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival
    Ming Wen An
    Department of Mathematics, Vassar College, Poughkeepsie, NY MWA Department of Biostatistics, Analytical Science, Takeda Pharmaceuticals, Deerfield, IL XD Department of Health Sciences Research, Mayo Clinic, Rochester, MN JM, DJS, SJM Biometrics and Data Management Department, Novartis Pharmaceuticals Corporation, East Hanover, NJ YH Department of Oncology, Mayo Clinic, Rochester, MN AG European Organisation for Research and Treatment of Cancer EORTC, Brussels, Belgium JB
    J Natl Cancer Inst 107:. 2015
    ..We sought to develop and validate clinically relevant, early assessment continuous tumor measurement-based metrics for predicting overall survival (OS) using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 data warehouse...
  46. pmc Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database
    Winson Y Cheung
    Winson Y Cheung, British Columbia Cancer Agency, Vancouver, British Columbia Chris O Callaghan, Queen s University, Kingston, Ontario, Canada Lindsay A Renfro, Axel Grothey, Steven R Alberts, and Daniel J Sargent, Mayo Clinic, Rochester, MN David Kerr, University of Oxford, Oxford Chris Twelves, University of Leeds and St James Institute of Oncology, Leeds, United Kingdom Aimery de Gramont, Franco British Institute, Levallois Perret Thierry Andre, Hospital Saint Antoine and Pierre and Marie Curie University, Paris Jean Francois Seitz, La Timone Hospital, Aix Marseille University, Marseille, France Leonard B Saltz, Memorial Sloan Kettering Cancer Center, New York, NY Katherine A Guthrie, Fred Hutchinson Cancer Center, Seattle, WA Roberto Labianca, Ospedale Giovanni XXIII, Bergamo Guido Francini, University of Siena, Siena, Italy Eric Van Cutsem, University Hospital Leuven, Harvard Medical School
    J Clin Oncol 34:1182-9. 2016
    ..We aimed to characterize the determinants of early mortality in a large cohort of colon cancer trial participants...
  47. pmc MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy
    Collin Zimmerman
    Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA
    Support Care Cancer 24:1071-8. 2016
    ..The purpose of this randomized, placebo-controlled, double-blinded pilot study was to obtain additional data to support conducting a phase III trial to test the use of venlafaxine to prevent oxaliplatin neurotoxicity...
  48. pmc Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system databa
    Qian Shi
    Qian Shi, Axel Grothey, and Daniel J Sargent, Mayo Clinic, Rochester, MN Aimery de Gramont and Benoist Chibaudel, Hospital Saint Antoine Christophe Tournigand, Université Paris Est Créteil, Paris Jean Yves Douillard, Institute of Cancer Research in Western, St Herblain, France John Zalcberg, Monash University Niall C Tebbutt, Austin Health, Melbourne, Victoria, Australia Hans Joachim Schmoll, Martin Luther University, Halle Rainer Porschen, Klinikum Bremen Ost, Bremen Volker Heinemann, University of Munich, München Carsten Bokemeyer, University Hospital, Hamburg Eppendorf, Germany Matthew T Seymour, Cancer Research UK Clincal Center, Leeds Richard Adams, Cardiff University, Cardiff, United Kingdom Leonard Saltz, Memorial Sloan Kettering Cancer Center, New York, NY Richard M Goldberg, Ohio State University, Columbus, OH Cornelis J A Punt, Academic Medical Center, Amsterdam, Arizona Cancer Center
    J Clin Oncol 33:22-8. 2015
    ..Because mCRC treatment has advanced in the last decade with extended OS, this surrogacy requires re-examination...
  49. ncbi request reprint Clinical trial designs for prospective validation of biomarkers
    Sumithra J Mandrekar
    Division of Biostatistics, Mayo Clinic, Rochester, Minnesota, USA
    Am J Pharmacogenomics 5:317-25. 2005
    ..Additional research is clearly warranted to achieve the goal of 'predictive oncology'...
  50. ncbi request reprint Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
    Daniel J Sargent
    North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:8664-70. 2005
    ..A shorter-term end point providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice...
  51. pmc Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254
    Gita Thanarajasingam
    Division of Hematology, Mayo Clinic, Rochester, MN, USA Electronic address
    Lancet Oncol 17:663-70. 2016
    ..Conventional analysis and display of maximum grade adverse events do not capture toxicity profiles that evolve over time or longer lasting, lower grade toxic effects; we aimed to address this shortcoming in this study...
  52. ncbi request reprint Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after st
    Axel Grothey
    Mayo Clinic, Rochester, MN Ospedale San Martino, Genova, Italy Ospedale Niguarda Cà Granda, Milan, Italy University of Pisa, Pisa, Italy CRLC Val d Aurelle, Montpellier, France University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA National Cancer Center Hospital East, Kashiwa, Japan Bayer HealthCare Pharmaceuticals, Montville, NJ Bayer Pharma AG, Berlin, Germany University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 30:LBA385. 2012
    ..The phase III CORRECT trial was conducted to evaluate efficacy and safety of regorafenib in pts with mCRC who had progressed after all approved standard therapies...
  53. pmc Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer
    Evanthia Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 16:979-84. 2008
    ..5 months from treatment initiation. Rexin-G is well tolerated in doses up to 6 x 10(11) CFU in patients with recurrent pancreatic cancer, but there was no evidence of clinical antitumor activity...
  54. doi request reprint The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials
    Gita Thanarajasingam
    Department of Medical Oncology GT, JH, AG and Alliance Statistics and Data Center JAS, Mayo Clinic, Rochester, MN
    J Natl Cancer Inst 107:. 2015
    ....
  55. pmc Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147
    Jocelin Huang
    Department of Oncology, Mayo Clinic Rochester, Rochester, MN
    Clin Colorectal Cancer 13:100-9. 2014
    ..When other contemporary trials demonstrated no benefit to using irinotecan as adjuvant therapy, the FOLFIRI-containing arms were discontinued. We report the clinical outcomes for patients randomized to FOLFIRI with or without cetuximab...
  56. ncbi request reprint Adolescent and young adult colorectal cancer
    Joleen M Hubbard
    From the Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota
    J Natl Compr Canc Netw 11:1219-25. 2013
    ..Future studies should seek to increase understanding of the distinct tumor biology of AYA patients with CRC and the consequences of treatment interventions to optimize outcomes for this population. ..
  57. doi request reprint Treatment options for advanced pancreatic cancer: a review
    Rahma Warsame
    Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Expert Rev Anticancer Ther 12:1327-36. 2012
    ..This review will focus on the current treatment options, the evolution of targeted therapy, novel agents on the horizon and potential options to ameliorate chemoresistance...
  58. pmc Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications
    Mark A Lewis
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Oncologist 17:725-31. 2012
    ..We examined length of stay (LOS), laboratory patterns, medication usage, morbidity, and mortality of patients hospitalized after HAE for metastatic neuroendocrine tumors...
  59. pmc Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas
    Harry H Yoon
    Departments of Medical Oncology, Health Sciences Research, Cytogenetics, Anatomic Pathology, Cancer Center, Laboratory Medicine and Pathology, and Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Cancer Res 18:546-54. 2012
    ..We examined the frequency, tumor characteristics, and prognostic impact of HER2 protein expression and gene amplification in patients with curatively resected esophageal adenocarcinoma (EAC)...
  60. pmc Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer
    Daniel J Sargent
    Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    J Clin Oncol 27:1948-55. 2009
    ..Clinical trials typically enroll less than 10% of patients with a PS of 2 (PS2); thus, the benefit of systemic chemotherapy in PS2 patients is uncertain...
  61. doi request reprint Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies
    Sherry Wolf
    Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Eur J Cancer 44:1507-15. 2008
    ..Lastly, paclitaxel causes a unique acute pain syndrome which has been hypothesised to be caused by neurologic injury. No drugs, to date, have been proven to prevent this toxicity...
  62. ncbi request reprint Symptom control trials: a 20-year experience
    Charles L Loprinzi
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Support Oncol 5:119-25, 128. 2007
    ....
  63. doi request reprint Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer
    Ben Y Zhang
    Department of Oncology, Mayo Clinic, Rochester, MN
    Clin Colorectal Cancer . 2016
    ....
  64. pmc Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study
    Pashtoon M Kasi
    Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, 55905, MN, USA
    BMC Cancer 16:467. 2016
    ..To explore this finding further, a cohort study was designed based on outcome data from three centers in United States and one from Japan...
  65. ncbi request reprint Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice
    Deirdre R Pachman
    From the department of Oncology, Robert D and Patricia E Kern Center for the Science of Health Care Delivery, and health care policy and research, Mayo Clinic, Rochester, Minnesota and Optum Labs, Cambridge, Massachusetts
    J Natl Compr Canc Netw 13:1097-101. 2015
    ..This article explores how accumulating evidence for and against the use of CaMg for preventing oxaliplatin-induced neuropathy has impacted clinical practice...
  66. pmc Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies
    Joleen M Hubbard
    Mayo Clinic Rochester, 200 First Street, SW, Rochester, MN, 55905, USA
    Invest New Drugs 34:96-103. 2016
    ..This phase I trial sought to determine the maximum tolerable dose (MTD) of bevacizumab and sorafenib combined with standard cytotoxic therapy for advanced gastrointestinal (GI) cancers...
  67. pmc Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)
    Deirdre R Pachman
    Deirdre R Pachman, Rui Qin, Drew K Seisler, Andreas S Beutler, Lauren E Ta, Jacqueline M Lafky, Kathryn J Ruddy, Nathan P Staff, Axel Grothey, and Charles L Loprinzi, Mayo Clinic, Rochester, MN Ellen M L Smith, University of Michigan, Ann Arbor, MI Nina D Wagner Johnston, Washington University School of Medicine, Saint Louis, MO and Shaker Dakhil, Cancer Center of Kansas, Wichita, KS
    J Clin Oncol 33:3416-22. 2015
    ..Given that the clinical course of oxaliplatin-induced neuropathy is not well defined, the current study was performed to better understand clinical parameters associated with its presentation...
  68. doi request reprint Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study
    Axel Grothey
    Mayo Clinic, Medical Oncology, Rochester, MN, USA
    Pharmacoepidemiol Drug Saf 23:726-34. 2014
    ....
  69. doi request reprint Is obesity an advantage in patients with colorectal cancer?
    Pashtoon Murtaza Kasi
    a 1 Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Expert Rev Gastroenterol Hepatol 9:1339-42. 2015
    ..In patients already diagnosed with metastatic disease, studying how body weight affects tumor biology and treatment-related decisions are important considerations. ..
  70. doi request reprint Colorectal cancer in 2014: progress in defining first-line and maintenance therapies
    Joleen M Hubbard
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Nat Rev Clin Oncol 12:73-4. 2015
    ....
  71. doi request reprint Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers
    Pashtoon Murtaza Kasi
    Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN, USA
    Expert Rev Gastroenterol Hepatol 9:273-6. 2015
    ..The focus of this editorial is to highlight some of these issues alongside results of some of the important clinical trials and other studies presented at the American Society of Clinical Oncology meeting last year. ..
  72. pmc Systemic therapy for elderly patients with gastrointestinal cancer
    Joleen M Hubbard
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Clin Med Insights Oncol 5:89-99. 2011
    ..This article reviews the evidence on chemotherapeutic regimens in the elderly with colorectal, pancreatic, and gastroesophageal cancers, and discusses a practical approach to provide the best outcomes for older patients...
  73. ncbi request reprint [Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms]
    Axel Grothey
    Innere Klinik IV, Hämatologie Onkologie, Martin Luther Universitat Halle Wittenberg
    Med Klin (Munich) 97:270-7. 2002
    ..However, it remains unclear if these concepts have made inroads into clinical practice...
  74. ncbi request reprint Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda)
    Hilde Marsé
    University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Eur J Oncol Nurs 8:S16-30. 2004
    ..Consequently, oncology nurses will be assuming a more significant and pivotal role in the efficient education and support of patients during home-based therapy with capecitabine...
  75. ncbi request reprint Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers
    Karin Jordan
    Department of Hematology and Oncology, University of Halle, Germany
    Clin Colorectal Cancer 4:46-50. 2004
    ..This trial served as basis for a randomized multicenter phase II study comparing capecitabine/oxaliplatin and capecitabine/irinotecan as first-line therapy in patients with advanced colorectal cancer...
  76. ncbi request reprint Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting
    Karin Jordan
    Department of Internal Medicine IV, Hematology Oncology, Martin Luther University Halle Wittenberg, Germany
    Onkologie 28:88-92. 2005
    ..To assess the antiemetic efficacy of an oral suspension of granisetron/dexamethasone in patients receiving chemotherapy and to determine whether quality-of-life parameters influence the risk for postchemotherapy nausea and vomiting (PCNV)...
  77. ncbi request reprint Costs of treatment of colorectal cancer in different settings in Germany
    Klaus Hieke
    NEOS Health, Parkstrasse 28, 4102, Binningen, Switzerland
    Eur J Health Econ 5:270-3. 2004
    ..Substantial cost savings without incurring losses to providers may be realized if patients are transferred from the hospital setting to the office-based setting and treated with capecitabine...
  78. ncbi request reprint Targeting the right target: epidermal growth factor receptor-directed individualized therapy
    Axel Grothey
    Clin Colorectal Cancer 7:S6-7. 2007
  79. ncbi request reprint Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab
    Lee M Ellis
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 23:4853-5. 2005
  80. ncbi request reprint Oxaliplatin-safety profile: neurotoxicity
    Axel Grothey
    Department of Hematology Oncology, Martin Luther University Halle Wittenberg, Halle, Germany
    Semin Oncol 30:5-13. 2003
    ..The predictability of neurotoxicity associated with oxaliplatin-based therapy should allow patients and doctors to develop strategies to manage this side effect in view of the individual patient's clinical situation...
  81. ncbi request reprint Antiangiogenic therapy in cancer: a new era has begun
    Axel Grothey
    Oncology (Williston Park) 19:5-6. 2005
  82. ncbi request reprint Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway
    George P Kim
    Division of Hematology Oncology, Mayo Clinic Jacksonville, FL, USA
    Clin Colorectal Cancer 5:S89-97. 2005
    ..This article reviews the impact of EGF receptor inhibitors on improving survival in CRC when combined with oxaliplatin-containing regimens...
  83. ncbi request reprint Sound footing or slippery slope? The value of secondary analyses of randomized trials
    Daniel Sargent
    J Clin Oncol 25:3191-3. 2007
  84. doi request reprint Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set
    MICHAEL J O'CONNELL
    National Surgical Adjuvant Breast and Bowel Project Operations Office, Pittsburgh, PA 15212 5234, USA
    J Clin Oncol 26:2336-41. 2008
    ....
  85. ncbi request reprint Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer
    Hendrik Tobias Arkenau
    Hospital Bremen East, Germany
    Clin Colorectal Cancer 7:60-4. 2008
    ....
  86. ncbi request reprint End points in advanced colon cancer clinical trials: a review and proposal
    Carmen Allegra
    University of Florida, Gainsville, FL, USA
    J Clin Oncol 25:3572-5. 2007
  87. ncbi request reprint Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity
    Howard S Hochster
    J Clin Oncol 25:4028-9. 2007
  88. ncbi request reprint Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group
    Rainer Porschen
    Clinic of Internal Medicine, Hospital Bremen East, Bremen, Germany
    J Clin Oncol 25:4217-23. 2007
    ..To compare the use of capecitabine plus oxaliplatin (CAPOX) with infusional fluorouracil (FU)/folinic acid plus oxaliplatin (FUFOX) as first-line therapy for patients with metastatic colorectal cancer (MCRC)...
  89. ncbi request reprint Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial
    Preeta Tyagi
    Physicians Education Resource, Dallas, TX, USA
    Clin Colorectal Cancer 6:261-4. 2006
    ..8.6 months; HR, 0.89; P = 0.1871) prolonged PFS compared with respective placebo arms; however, it did not show statistical significance with the FOLFOX4 regimen. The adverse events were manageable and comparable between treatment arms...
  90. ncbi request reprint The continuum of care: a paradigm for the management of metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 12:38-50. 2007
    ....
  91. ncbi request reprint Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line
    Axel Grothey
    J Clin Oncol 23:9441-2. 2005
  92. doi request reprint New lessons from "old" chemotherapy in colorectal cancer
    Axel Grothey
    J Clin Oncol 26:4532-4. 2008
  93. ncbi request reprint Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer
    Tara Beers Gibson
    CIG Medical Group, LP, Dallas, TX, USA
    Clin Colorectal Cancer 6:29-31. 2006
    ..Further clinical studies re ongoing and planned to test panitumumab in combination with chemotherapy in first-line therapy of advanced-stage CRC and adjuvant treatment of colon cancer...
  94. ncbi request reprint Selection of patients for resection of hepatic colorectal metastases: expert consensus statement
    Chusilp Charnsangavej
    Department of Radiology, M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 13:1261-8. 2006
  95. ncbi request reprint Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis
    Karin Jordan
    Department for Hematology Oncology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120, Halle, Germany
    Support Care Cancer 13:26-31. 2005
    ....
  96. ncbi request reprint New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference
    Lee S Rosen
    Premiere Oncology, Santa Monica, CA 90404, USA
    Clin Cancer Res 13:6853s-6s. 2007
    ....
  97. ncbi request reprint Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer
    Thomas Mueller
    Department of Hematology Oncology, Martin Luther University of Halle Wittenberg, 06120 Halle, Germany
    Cancer Res 63:513-21. 2003
    ..However, additional defining and eventually targeting the exact molecular mechanism blocking caspase-9 activation might lead to more selective therapeutic approaches to overcome cisplatin resistance in germ cell cancer...
  98. ncbi request reprint Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data
    Anna D Wagner
    First Department of Medicine, Coordinating Centre for Clinical Trials, and Institute of Medical Epidemiology, Biostatistics and Informatics, Martin Luther University Halle Wittenberg, Halle Saale, Germany
    J Clin Oncol 24:2903-9. 2006
    ..This systematic review and meta-analysis were performed to assess the efficacy and tolerability of chemotherapy in patients with advanced gastric cancer...
  99. ncbi request reprint Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy
    Karin Jordan
    Internal Medicine IV, Hematology Oncology, Martin Luther University Halle Wittenberg, Halle Saale, Germany
    Eur J Haematol 74:263-6. 2005
    ..Rituximab was continued for another 6 months with subsequent consolidation radiotherapy. This is the first report of an enduring complete remission (20 months) of a non-CNS lymphomatoid granulomatosis treated with rituximab...